Arthromil™ - Research Brief

I Product Info I Ingredients I Recommended Use I Clinical Trials I Research Brief I References

arthromill

Indication: impaired joint mobility, weakened immunity, increased physical activity.

Main Actions: increases joint flexibility, promotes healthy cholesterol, strengthens the immune system, helps to maintain good intestinal health.

Ingredients (per 1 tablet): MicroLactin™ (Milk Protein Concentrate) – 500 mg, calcium – 143.5 mg.

 

Order this item

Low USA domestic & international

shipping

Arthromil™ - Research Brief:

Milk is a complex substance consisting of fat, casein, whey proteins (which include IgG antibodies), milk sugars, vitamins, and minerals. Milk has traditionally been viewed only from a nutritional standpoint. We all know that the macronutrients in milk (calcium, vitamins, proteins, etc.) can benefit our health. However, SMBI’s research has identified that milk also contains micronutrients that have unique and useful biological activity. However, this activity occurs at a very low level in normally processed milk. 

Over the past 30 years SMBI researchers have discovered that stimulation of a cow’s immune system can enhance the expression of the many biologically useful micronutrients that naturally occur in milk. This work is built upon the theories and work of Dr. William Petersen, Professor of Dairy Science at the University of Minnesota. It was Dr. Petersen who pioneered the concept of "immune milk" in the 1950’s. Petersen confirmed the health benefits of milk from cows treated with special immune stimulants. Petersen demonstrated that the cow’s natural process of creating antibodies to the antigens present in the immune stimulant was passed to the milk and could benefit anyone who consumed the milk. It was SMBI that put forth the money, effort and scientific methods necessary to understand the "how and why" of this phenomenon. SMBI has spent years determining both how to enhance the expression of the micronutrients in milk and which fractions of milk contain the micronutrients. Furthermore, SMBI has developed commercial-scale processes to separate and manufacture the micronutrients.
SMBI’s research has led to the development of a potent fraction of milk called MicroLactin™. This fraction contains the same biological activity of intact milk at a much lower dose. It is anticipated that even further breakthroughs will be made and even more potent, bioactive fractions will soon be made available to consumers.


8,000 Case Histories Reveal the Power of Milk Micronutrients

Continuously, from 1960 to 1996, SMBI distributed, free of charge, a powdered drink containing milk micronutrients to consumers around its headquarters in Cincinnati, Ohio. Consumers were asked to complete and return survey forms to the company. This 35 year study, which documented over 8,000 case histories, has become known as the Ohio Survey.
The Ohio Survey is a landmark study of the safety and efficacy of SMBI’s milk micronutrients. We know of no other dietary supplement with such extensive documentation of use and effects. The intent of the Survey was to gather a large database of consumer usage to understand both the safety and benefits of daily consumption of the milk micronutrients. Data gathered from participants included basic background information on sex, age, weight, height, doctor’s or subject’s assessment of health status including any known ailments, and a general health history with documentation of any medications. Participants were asked to consume 45 grams of powder containing the special milk micronutrients, which was typically reconstituted with water and consumed once daily as a beverage. Participants were asked to periodically complete survey forms to document their health status and any side effects. 

During the first fifteen years of the survey the company documented 3,545 case histories. The results showed that the product was well tolerated and, more importantly, that the users perceived significant health benefits. In the early 1990’s SMBI computerized the database and during the last five years of the Survey, documented another 4,867 consumer experiences with the supplement. The accompanying table shows the total number of participants, their reported conditions at the beginning of the survey and the percentage that reported improvement. As can be seen by the data, 73.5% of all consumers reported an improvement in their overall health. 

SMBI used the results of the Ohio Survey to steer its clinical research efforts. Since the Survey was not a controlled clinical trial, the company took the further step of conducting a multitude of controlled clinical trials. These human trials, conducted by independent research organizations under controlled circumstances, confirmed many of the findings in the Ohio Survey.

 

OHIO SURVEY RESULTS 1992-1996

 

Condition

Total Participants

Percent Reporting Improvements

All Conditions

4,867

73.5%

Joint Pain

2,737

83.7%

Cholesterol

1,123

71.5%

Blood Pressure

714

66.4%

Fatigue

803

74.2%

Sleep Problems

525

69.3%

Indigestion

287

70.7%

Allergies

379

67.8%

Lung Conditions

169

59.2%

Skin Conditions

209

54.1%

 

Overwhelming Clinical Evidence Supports Product Claims

 

In an effort to validate the dramatic findings of the Ohio Survey, SMBI scientists designed and conducted a multitude of clinical trials in various health areas. Since 1975, the company has completed 16 well-controlled trials. These studies were all conducted by independent clinical research organization or at major research universities. In total, over 700 subjects have been studied and documented.

This research supported the findings of the Ohio Survey. The strength and validity of the results in these clinical trials have supported the issue of more than 200 worldwide patents on the uses of SMBI’s micronutrient technology.

 

Summary of Clinical Activity 

SMBI Product

Indication

# Patients

Date

Duration

Stolle

Rheumatoid Arthritis

20

1975

24 weeks

Milk

Juvenile Arthritis

10

1992

24 weeks

Powder (8-100)

Rheumatoid Arthritis

211

1993

24 weeks

Powder (8-100)

Osteoarthritis

34

1992

6 weeks

Powder (8-100)

Cholesterol

20

1985

6 weeks

Powder (8-100)

Cholesterol

11

1989

8 weeks

Powder (8-100)

Cholesterol

30

1992

10 weeks

Powder (8-100)

Cholesterol

167

1994

8 weeks

Powder (8-100)

Hypertension

27

1993

2 weeks

Powder (8-100)

Runners

20

1993

24 weeks

Stolle

Cholesterol

19

1993

12 weeks

Milk plus

Hypertension

30

1994

12 weeks

WPC (S-200)

Psoriasis

9

1993

12 weeks

Milk plus

Psoriasis

49

1994

12 weeks

Permeate (S-300)

Ragweed

65

1993

6 weeks

Stolle WPC

Cholesterol

29

1993

12 weeks

 

Clinical Totals: 751 Patients